ScreenerHero

RARE Ultragenyx Pharmaceutical Inc.

NAS · US · Healthcare · Biotechnology · ultragenyx.com
14.89USD+2.97%Mkt Cap: 1.47B $P/E: —

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in N…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.47B USD
Enterprise Value2.34B USD
Revenue (TTM)717.00M USD
Gross Profit564.00M USD
Net Income (TTM)-575.00M USD
Revenue/Share7.13 USD
Last Price14.89 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1.4K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)21.37
PEG—
EV/EBITDA-5.03
EV/Revenue3.26
P/S1.99
P/B-4.89
EPS (TTM)-5.80
EPS (Forward)0.68
52W Range
12.738% of range39.89
52W High39.89 USD
52W Low12.73 USD
Profitability
Gross Margin83.80%
Oper. Margin-35.05%
EBITDA Margin-64.85%
Profit Margin-85.44%
ROE718.75%
ROA-37.53%
Growth
Revenue Growth28.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-466.00M USD
CapEx (TTM)21.00M USD
FCF Margin-30.93%
FCF Yield-15.11%
Net Debt910.00M USD
Net Debt/EBITDA-1.96
Balance Sheet
Debt/Equity-0.45
Current Ratio1.73
Quick Ratio1.41
Book Value/Sh-2.96 USD
Cash/Share2.97 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.0 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)28.05 USD
Upside (mean)+88.4%
Target Range18.00 USD – 40.00 USD
18.00+88.4% to mean40.00
# Analysts19
Ownership
Shares Out.98.59M
Float80.42M
Insiders3.44%
Institutions112.49%
Short Interest
Short Ratio3.5d
Short % Float17.38%
Short % Out.16.81%
Shares Short16.57M
Short (prev mo.)15.89M
Technical
SMA 5020.94 (-28.9%)
SMA 20023.99 (-37.9%)
Beta0.35
S&P 52W Chg16.45%
Avg Vol (30d)5.22M
Avg Vol (10d)4.95M
Technical Indicators
RSI (14)36.5
MACD-1.9798
MACD Signal-2.4219
MACD Hist.+0.4421
BB Upper15.81 USD
BB Middle14.64 USD
BB Lower13.47 USD
BB Width15.98%
ATR (14)1.130 USD
Vol Ratio (20d)0.62x